UNCY
Unicycive Therapeutics Inc
4.20$
-1.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -27.0% | +269.1% | -14.7% | -13.7% | -17.9% | -11.8% | +7.3% | +68.7% | -2.9% | +31.1% | +11.8% | |
| – | -27.8% | +285.7% | -14.7% | -14.3% | -18.0% | -11.6% | +8.0% | +70.3% | -2.6% | +29.8% | +12.2% | |
| – | -32.4% | +404.4% | -14.6% | -22.6% | -19.2% | -24.4% | +12.9% | +91.2% | -31.6% | +28.0% | +18.2% | |
| – | -32.4% | +404.4% | -14.6% | -22.6% | -19.2% | -24.4% | +12.9% | +91.2% | -3.3% | +32.3% | +12.5% | |
| – | +12.4% | +70.3% | -56.4% | -19.7% | +126.0% | -31.2% | -18.6% | -3.2% | +44.2% | +41.0% | -29.7% | |
| – | +13.4% | +72.7% | -56.8% | -20.1% | +130.6% | -30.9% | -18.6% | -3.2% | +44.2% | +39.9% | -29.4% | |
| – | +9.9% | -0.6% | +5.0% | +50.6% | +21.0% | +5.8% | -31.4% | +6.1% | -60.6% | +263.8% | -14.9% | |
| – | -17.1% | +42.6% | +17.5% | -60.2% | +76.3% | +29.5% | -43.4% | +1.3% | -58.0% | +236.9% | +120.3% | |
| – | -210.9% | – | +44.2% | -11.1% | -73.3% | +51.7% | +45.8% | +128.1% | -19.4% | +24.9% | +41.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +6.5% | +0.5% | +8.6% | +134.6% | -12.3% | +58.8% | -0.7% | +46.8% | +10.1% | +20.2% | +12.6% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.